Alkermes (ALKS) Earning Somewhat Positive Press Coverage, Analysis Finds

Headlines about Alkermes (NASDAQ:ALKS) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alkermes earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5725444871458 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Alkermes (NASDAQ:ALKS) traded down $0.26 during trading hours on Friday, hitting $58.71. The stock had a trading volume of 639,774 shares, compared to its average volume of 896,700. Alkermes has a fifty-two week low of $46.42 and a fifty-two week high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. The company has a market cap of $9,000.00, a PE ratio of -52.89 and a beta of 2.13.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.09) EPS. equities analysts anticipate that Alkermes will post -0.59 earnings per share for the current year.

A number of research analysts have issued reports on ALKS shares. Barclays cut Alkermes from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $66.00 to $50.00 in a report on Monday, October 16th. Mizuho set a $81.00 target price on Alkermes and gave the company a “buy” rating in a research note on Saturday, October 21st. ValuEngine lowered Alkermes from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Citigroup set a $62.00 target price on Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. Finally, Credit Suisse Group lowered their price objective on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Alkermes presently has an average rating of “Hold” and an average price target of $63.33.

In other news, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $54.99, for a total transaction of $54,990.00. Following the sale, the director now owns 9,000 shares in the company, valued at approximately $494,910. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP James M. Frates sold 20,932 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total value of $995,944.56. The disclosure for this sale can be found here. Insiders sold a total of 136,417 shares of company stock worth $7,259,391 in the last 90 days. Company insiders own 5.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Alkermes (ALKS) Earning Somewhat Positive Press Coverage, Analysis Finds” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with's FREE daily email newsletter.

Leave a Reply